Replimune Group Inc.

Clinical research is centred on melanoma, including metastatic melanoma and advanced melanoma, with a strong focus on immune-based treatment approaches and disease control in patients with limited options.

• Metastatic melanoma
• Anti-PD1–refractory melanoma
• Immune checkpoint inhibitor combinations

Interest extends to patients whose disease has progressed after prior immunotherapy, reflecting a therapeutic emphasis on checkpoint blockade combinations in difficult-to-treat cutaneous malignancies.